The Centers for Disease Control (CDC) and Substance Abuse and Mental Health Services Administration (SAMHSA) announced meetings to be held this summer related to public health and marijuana. The CDC’s Board of Scientific Counselors will convene for a two-day meeting, July 16–17, 2019, to discuss a wide variety of topics, including the role of the CDC’s National Center for Injury Prevention and Control in “addressing public health concerns related to marijuana.” This portion of the meeting will be held on July 17, will be open to the public and will allot 15 minutes for public comments at the end of the session from 3:40–3:55 pm on July 17, 2019.
As described in the Federal Register notice of the meetings, the Board of Scientific Counselors conducts and assists other appropriate public health authorities, scientific institutions and scientists in the conduct of research, investigations, demonstrations and studies relating to the causes, diagnosis, treatment, control and prevention of physical and mental diseases and other impairments; assists states and their political subdivisions in preventing and suppressing communicable and non-communicable diseases and other preventable conditions; and conducts and assists in research and control activities related to injury. The Board has the ability to make recommendations regarding policies, strategies, objectives and priorities; to provide evidence in injury prevention-related research and programs; and to provide advice on the appropriate balance of intramural and extramural research, the structure, progress and performance of intramural programs.
The CDC notice can be found here.
In addition, on June 11–12, 2019, members of the SAMHSA Drug Testing Advisory Board (DTAB) will meet to discuss, in part, proposed Mandatory Guidelines for Federal Workplace Drug Testing Programs, emerging issues surrounding marijuana legalization and the impact of cannabis laws on drug testing.
As described on the DTAB website, the DTAB advises the Agency based on an ongoing review of the direction, scope, balance and emphasis of the Agency’s drug testing activities and the drug testing laboratory certification program. DTAB is charged with reviewing the Agency’s program for national laboratory certification for Federal workplace drug testing programs and has the ability to recommend areas for emphasis or de-emphasis, new or changed directions, and mechanisms or approaches for implementing recommendations.
The SAMHSA notice can be found here.
Date/Time: June 11, 2019, 9:30 am – 4:30 pm EDT (OPEN) and June 12, 2019, 9:00 – 10:00 am EDT (OPEN); June 12, 2019, 10:00 am – 4:00 pm EDT (CLOSED)
Location: Hilton Washington DC/Rockville Hotel & Executive Meeting Center, 1750 Rockville Pike, Rockville, MD 20852
Meeting registration information can be completed at https://snacregister.samhsa.gov/MeetingList.aspx. Web conference and call information will be sent after completing registration.
Date/Time: July 16, 2019, 1:00 – 3:00 pm EDT (CLOSED) and July 17, 2019, 9:00 am – 5:00 pm EDT (OPEN)
Location: 4770 Buford Highway NE, Atlanta, GA 30341; Teleconference Number: 1-866-692-4541, Participant Code: 12365987
These meetings were earlier reported by Marijuana Moment.